MRNA
NASDAQ · Biotechnology
Moderna Inc
$154.04
-4.03 (-2.55%)
MRNA News30 articles
Moderna Jumps 10% as Cancer Vaccine Trial Hits Key Goals
Moderna shares surged 9.93% after its cancer vaccine intismeran met two Phase 3 endpoints, adding $5.6B in market value. Full efficacy data remain undisclosed.
Moderna Slides 3.4% as $55B Valuation Faces Cancer Vaccine Commercial Test
Moderna (MRNA) dropped 3.4% Friday, but the stock is still up 130% on melanoma vaccine hopes. Analysts see $1B in sales by 2030, yet commercial hurdles and trial setbacks persist.
Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan
Novavax shares slipped 0.6% to $9.00 after regulatory approvals for its updated vaccine in the US, EU, and Japan. The company now relies on partners like Sanofi for commercialization, with royalties expected but not yet in guidance.
Moderna Drops 3.4% on $2.6B Convertible Offering Amid Cancer Vaccine Rally
Moderna shares slid 3.4% to $137.86 after pricing a $2.6B zero-coupon convertible notes offering, sparking dilution worries and cooling the recent cancer-vaccine rally.
Moderna Drops 5% on $2B Convertible Debt Sale
Moderna shares slid 5% after the company unveiled a $2B convertible notes offering, erasing $3B from its market cap. The financing follows a recent surge in its cancer-vaccine prospects.
Moderna Soars 14% on Cancer Vaccine Optimism, Adds $8B in Value
Moderna's stock surged 14.4% after a Wolfe Research upgrade, adding $8 billion in market value. The rally follows promising melanoma vaccine results, but analysts caution on profitability.
Moderna Surges 12% as Wolfe Drops Bearish Stance on Cancer Vaccine
Moderna shares surged 12% after Wolfe Research upgraded the stock, citing a clearer approval path and $9.2 billion peak sales potential for its cancer vaccine intismeran.
Alibaba's $10B AI Fundraise Rattles Overnight Trade; Chip Stocks Slide
Alibaba's $10.2B AI placement weighs on ADRs overnight, joining a memory-chip selloff. Futures flat ahead of Nvidia earnings.
Moderna's Cancer Vaccine Rally Outpaces Wall Street Targets
Moderna's stock soared 129% in a week on positive cancer vaccine data, leaving analyst targets far behind. The average price target is 45.7% below the current price.
Space ETF and Micron Drive Late-Session Gains in Asian Markets
Asian markets ended mixed on Friday, with Hong Kong and Korea leading gains. KASE's late session saw a space ETF and Micron surge, reflecting a broader risk-on tone.
Moderna's $28B Surge: Melanoma Trial Sparks Investor Frenzy
Moderna's market cap jumped $28B after a successful Phase 3 melanoma vaccine trial, but shares remain far above analyst targets.
Gold's Rally Signals Lingering Caution as Futures Edge Higher
A modest bounce in U.S. equity futures is being overshadowed by a continued bid in gold, which rose 3.6% this week to $4,540, as investors hedge against persistent yield and oil pressures.
MRK Surges 13% on Cancer Vaccine Data, Market Cap Jumps $44B
Merck (MRK) shares soared 13.3% to $153.12 after promising Phase 3 data for its melanoma vaccine with Moderna (MRNA), boosting market cap by $44.4B.
S&P 500 Recovers Most of Tuesday's Loss, Healthcare Leads as Tech Lags
The S&P 500 bounced back on Wednesday, recovering most of Tuesday's decline, but leadership shifted to healthcare as technology remained flat.
Moderna's mRNA Flu Shot Wins FDA Nod, But Sales Loom
Moderna secured FDA approval for its mRNA flu vaccine, but analysts see minimal revenue impact until late 2027, as the company's cash burn continues.
Pfizer Stock Rises as Sanofi Files Patent Suit Over COVID Vaccine Revenue
Pfizer shares gained 2.35% as Sanofi's patent lawsuit over Comirnaty targets past revenue rather than current sales, with modest financial risk relative to cash reserves.
Moderna Plunges 11% as EU Vaccine Deal Lacks Minimum Purchase Guarantee
Moderna stock dropped 11.3% after the EU's RSV vaccine deal lacked a minimum purchase commitment, adding to investor worries about sales and cash burn.
U.S. Futures Dip as June Jobs Data Misses Expectations
U.S. stock futures dipped Friday after ADP reported 98,000 private jobs in June, below forecasts. The 10-year yield neared 4.5%, pressuring banks and real estate. Moderna (MRNA) surged 10%.
Moderna Surges 10% as Flu Vaccine Hopes Add $2.9B to Market Cap
Moderna shares surged over 10% in after-hours trading, adding roughly $2.9 billion in market value as investor enthusiasm for its flu vaccine pipeline continues to build.
Moderna Stock Surges Past Analyst Targets Ahead of FDA Flu Vaccine Decision
Moderna shares surged over 12% Friday to $67.27, now trading above most Wall Street targets ahead of an FDA decision on its mRNA flu vaccine.
US Stock Futures Steady as Focus Shifts to Jobs Report
U.S. stock futures are steady as traders pivot from AI tech to the upcoming June jobs report. The S&P 500 fell 2% last week, led by a 7.9% plunge in semiconductors.
Tech Slide Masks Broader Market Resilience as AI Spending Concerns Mount
U.S. stocks ended mixed as a sharp decline in semiconductor stocks, led by AI-related concerns, triggered nearly $20 billion in tech fund outflows, while the broader market showed resilience.
Moderna Shares Surge on CAR-T Pipeline Plans, Outperform Sector
Moderna shares surged 12.6% after announcing new in vivo CAR-T pipeline plans, closing at $67.27, 52% above the mean analyst target but 14.5% below Piper Sandler's new $77 target.
Tech Selloff Deepens as Chip Index Plunges 5.3%; Jobs Data in Focus
The PHLX chip index fell 5.3% Friday and 7.9% for the week, overshadowing broader market gains. Tech funds lost nearly $20 billion as rising memory costs hit Apple and others. June payrolls data is due Thursday.
Dow Jones Recovers Weekly Gain as Tech Slide Halts Rally Above 52,000
The Dow Jones Industrial Average failed to hold above 52,000 for the third consecutive session, closing at 51,842.08, as a tech slide pressured the broader market.
Tech Sector Sees $20B Outflow as AI Trade Loses Steam
Nearly $20 billion exited tech sector funds last week, wiping out prior record inflows, as AI trade momentum cooled and chip stocks suffered their worst weekly drop since March.
Moderna stock surges $3.3B after unveiling in vivo CAR-T for autoimmune disease
Moderna shares surged 13.9%, adding $3.3 billion in market value after the company unveiled an in vivo CAR-T candidate for autoimmune disease at its Science Day, though near-term sales remain absent.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Moderna Shares Surge on Positive FDA Staff Review for mRNA Flu Vaccine
Moderna shares surged nearly 10% to $57.19 after FDA staff said data on its mRNA flu shot may support effectiveness in adults 65+, lowering regulatory risk ahead of a key advisory panel vote.
Moderna Stock Surges 8% Amid Nasdaq Rally, Cancer Vaccine Progress in Focus
Moderna shares surged nearly 8% to $49.64, tracking a broad Nasdaq rally. Investors are focused on the company's mRNA cancer vaccine pipeline after UK regulators cleared a new trial for Lynch syndrome.